Page last updated: 2024-09-05

sorafenib and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea

sorafenib has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea)
Trials
(3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea)
Recent Studies (post-2010) (3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea)
6,5207305,2511316127

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea (IC50)
Fibroblast growth factor receptor 1Homo sapiens (human)0.1093
Fibroblast growth factor receptor 2Homo sapiens (human)0.001
Fibroblast growth factor receptor 4Homo sapiens (human)0.0626
Fibroblast growth factor receptor 3Homo sapiens (human)0.1011
Fibroblast growth factor receptor 4Mus musculus (house mouse)0.561

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, WC; Hartano, S; Ho, RZW; Huynh, H; Koh, TS; Le, TBU; Lee, P; Prawira, A; Teo, XQ; Thng, CH; Tran, A; Vu, TC1

Other Studies

1 other study(ies) available for sorafenib and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea

ArticleYear
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Molecular imaging and biology, 2021, Volume: 23, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Contrast Media; Humans; Kinetics; Liver Neoplasms; Magnetic Resonance Imaging; Mice, SCID; Neovascularization, Pathologic; Perfusion; Phenylurea Compounds; Pyrimidines; Receptors, Fibroblast Growth Factor; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays

2021